Abbott Laboratories reported revenues of $6.64 billion in 2Q17, exceeding the analysts’ estimates. Abbott stock gained more than 4% the day of its 2Q17 results release, on July 20, 2017.
In 2Q17, Abbott reported EPS (earnings per share) of $0.62, compared with the analysts’ estimates of 0.61 per share.
According to the Wall Street analysts’ projections, Abbott Laboratories is expected to report a gross profit margin of 59.6% of total sales. In 2Q17, the gross profit margin of the company came in at ~59.8% of total sales.
Wall Street estimates, the company will report 3Q17 revenues of ~$6.71 billion, representing a YoY (year-over-year) growth of ~26.7%. In 3Q17, Abbott expects to register operational sales growth in the mid-single digits.
ABT’s adjusted research and development investment is expected to be ~7.5% of sales in 3Q17. However, its adjusted SG&A (selling, general, and administrative) expenditure is expected to be 29% of total sales, compared with its SG&A expenses of 30.1% of sales reported in 2Q17.
On October 11, 2017, ABT stock’s consensus 12-month target price was $56.3, which amounts to a ~1.6% return potential, based on its closing price of $55.4 on October 10, 2017. ABT is expected to reach the highest 12-month target price of $64, representing maximum upside potential of 15.5%.
The maximum downside risk of investing in ABT stock is expected to be around -15.2%, based on its lowest 12-month target price of $47.

Over all, Abbott is pretty stable and is expected to meet their third quarter estimate of 11% earnings increase and sales increased despite the impact of the weak euro on currency translation.

http://money.cnn.com/2000/10/10/companies/abbott/
http://marketrealist.com/2017/10/inside-abbotts-3q17-revenue-expectations-hit-or-miss/